Montara Therapeutics
Montara Therapeutics is a preclinical-stage biopharmaceutical company focused on developing safer, more efficacious therapies for neurological diseases using its proprietary BrainOnly™ platform. The platform aims to enable brain-specific pharmacology, preventing peripheral toxicities and expanding druggable targets for CNS diseases. Supported by top-tier investors, Montara is committed to revolutionizing brain-targeted drug discovery and development.
Industries
Nr. of Employees
small (1-50)
Products
Brain‑selective pharmacology platform
A platform technology that enables brain‑restricted pharmacology by pairing a brain‑penetrant target‑specific small molecule (chimera) with a non‑brain‑penetrant peripheral blocker to prevent peripheral on‑target activity and concentrate drug activity in the CNS.
Brain‑selective pharmacology platform
A platform technology that enables brain‑restricted pharmacology by pairing a brain‑penetrant target‑specific small molecule (chimera) with a non‑brain‑penetrant peripheral blocker to prevent peripheral on‑target activity and concentrate drug activity in the CNS.
Services
Collaborative research and partnerships to develop brain‑selective therapeutics, including grant‑funded projects and participation in therapeutic exchange programs to advance target‑specific programs and biomarkers.
Internal preclinical development services to progress discovery programs toward IND and development candidate (DC) status, including in vivo proof‑of‑concept and IND‑enabling studies.
Collaborative research and partnerships to develop brain‑selective therapeutics, including grant‑funded projects and participation in therapeutic exchange programs to advance target‑specific programs and biomarkers.
Internal preclinical development services to progress discovery programs toward IND and development candidate (DC) status, including in vivo proof‑of‑concept and IND‑enabling studies.
Expertise Areas
- Brain‑targeted drug discovery
- CNS preclinical development and IND enabling
- Medicinal chemistry and small‑molecule warhead engineering
- Combination pharmacology for organ‑restricted activity
Key Technologies
- Brain‑restricted pharmacology
- Two‑component combination therapy design
- Brain‑penetrant small‑molecule chimeras
- Non‑brain‑penetrant peripheral blockers
News & Updates
Montara Therapeutics announced the closing of a $20 million oversubscribed expansion of its Series Seed financing, bringing total seed funding to $28 million. The funding will support advancing lead epilepsy program to IND, progressing neurodegeneration program to development candidate, and accelerating a third undisclosed program. Troy Wilson was appointed as Chairman of the Board.
Montara Therapeutics received a $3.3 million grant from MJFF to develop BrainOnly™ Parkinson’s therapy targeting LRRK2, a genetically validated target with major drug development challenges. The platform aims to create brain-selective LRRK2 inhibitors that avoid irreversible peripheral toxicity.
Montara Therapeutics announced the closing of a $20 million oversubscribed expansion of its Series Seed financing, bringing total seed funding to $28 million. The funding will support advancing lead epilepsy program to IND, progressing neurodegeneration program to development candidate, and accelerating a third undisclosed program. Troy Wilson was appointed as Chairman of the Board.
Montara Therapeutics received a $3.3 million grant from MJFF to develop BrainOnly™ Parkinson’s therapy targeting LRRK2, a genetically validated target with major drug development challenges. The platform aims to create brain-selective LRRK2 inhibitors that avoid irreversible peripheral toxicity.